Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
47 Glioblastoma Trials near Philadelphia, PA
Power is an online platform that helps thousands of Glioblastoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerOptune + Temozolomide + Pembrolizumab for Brain Cancer
Philadelphia, Pennsylvania
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Pneumonitis, Other Malignancy, Others
Must Be Taking:Temozolomide
741 Participants Needed
Niraparib vs Temozolomide for Brain Cancer
Philadelphia, Pennsylvania
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main questions it aims to answer are:
Does niraparib improve progression-free survival (PFS) compared to TMZ?
Does niraparib improve overall survival (OS) compared to TMZ?
Participants will be randomly assigned to one of two treatment arms: niraparib or TMZ.
* study drug (Niraparib) or
* comparator drug (Temozolomide - which is the standard approved treatment for MGMT unmethylated glioblastoma).
The study medication will be taken daily while receiving standard of care radiation therapy (RT) for 6-7 weeks.
Participants may continue to take the niraparib or TMZ adjuvantly as long as the cancer does not get worse or completion of 6 cycles of treatment (TMZ). A total of 450 participants will be enrolled in the study.
Participants' tasks will include:
* Complete study visits as scheduled
* Complete a diary to record study medication
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Pneumonitis, Cirrhosis, Others
Must Not Be Taking:PARP Inhibitors
450 Participants Needed
Multiple Therapies for Glioblastoma
Philadelphia, Pennsylvania
This trial is testing various treatments for patients with newly diagnosed or returning brain cancer. It adjusts treatments based on how well patients are doing to find the most effective options. The goal is to improve survival rates by matching the best treatments to specific patient types.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Leptomeningeal Disease, QTc Prolongation, Others
Must Not Be Taking:Carmustine, Lomustine, Bevacizumab, Others
1030 Participants Needed
Combination Immunotherapy for Glioblastoma
Philadelphia, Pennsylvania
The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Bi-hemispheric Disease, Cardiac Disease, Others
Must Not Be Taking:Investigational Agents, Tumor Treating Fields
93 Participants Needed
Immunotherapy + Radiosurgery for Glioblastoma
Philadelphia, Pennsylvania
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Hepatitis, Cardiovascular, Others
Must Not Be Taking:Immunosuppressants, Antiretrovirals
39 Participants Needed
Niraparib + Optune for Glioblastoma
Philadelphia, Pennsylvania
This trial tests niraparib and TTFields in patients with recurrent glioblastoma. The electric fields weaken the cancer cells, and the drug stops them from fixing themselves, leading to cell death. Tumor-Treating Fields (TTFields) is a noninvasive cancer treatment that uses low-intensity alternating electric fields to disrupt cell division and has been FDA-approved for glioblastoma.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:22+
Key Eligibility Criteria
Disqualifiers:Age < 22, MDS/AML, Others
Must Not Be Taking:PARP Inhibitors
30 Participants Needed
Dabrafenib + Trametinib After Radiation for Brain Cancer
Philadelphia, Pennsylvania
This trial studies how well dabrafenib and trametinib work after radiation therapy in children and young adults with a specific type of brain tumor. These drugs help stop tumor growth by blocking signals that tell the cells to multiply. Dabrafenib has been developed and tested extensively for a specific type of skin cancer, showing effectiveness both alone and when used with trametinib.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:3 - 25
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Cardiac Disease, Others
Must Not Be Taking:Chemotherapy, Immunotherapy, Antidepressants, Others
58 Participants Needed
Veliparib + Radiation + Temozolomide for Brain Cancer
Philadelphia, Pennsylvania
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide may work better in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations compared to radiation therapy and temozolomide alone.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:3 - 25
Key Eligibility Criteria
Disqualifiers:Diffuse Astrocytoma, Oligodendrogliomas, PXA, Others
Must Not Be Taking:Anti-cancer Agents
38 Participants Needed
Combination Immunotherapy + Chemoradiation for Glioblastoma
Philadelphia, Pennsylvania
Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Immunodeficiency, Others
Must Not Be Taking:PD-1 Inhibitors, Idelalisib
52 Participants Needed
High-Dose Radiation + Temozolomide for Glioblastoma
Philadelphia, Pennsylvania
This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more effective than standard-dose radiation therapy with temozolomide in treating glioblastoma.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Prior Invasive Malignancy, Others
Must Be Taking:Temozolomide
606 Participants Needed
L19TNF + Lomustine for Glioblastoma
Philadelphia, Pennsylvania
The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Heart Disease, Others
Must Not Be Taking:Anticoagulants, Immunosuppressants
90 Participants Needed
Advanced Imaging for Glioblastoma
Philadelphia, Pennsylvania
* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET.
* To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism.
* To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, MRI Contraindications, Others
15 Participants Needed
CAR T-cell Therapy for Glioblastoma
Philadelphia, Pennsylvania
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy. This study will take place in two parts: an initial dose escalation phase followed by a dose exploration phase. In the dose expansion phase, the maximum tolerated dose (MTD) of CART-EGFR-IL13Ra2 cells will be determined using a standard 3+3 design. Once the MTD has been determined, the dose exploration phase will allow for further identification of a recommended dose for expansion (RDE) as well as the safety and feasibility of alternative dosing schedules.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Hepatitis, Cardiovascular, Autoimmune, Others
Must Not Be Taking:Immunosuppressants, Bevacizumab
21 Participants Needed
ONC206 + Radiation Therapy for Brain Tumor
Philadelphia, Pennsylvania
This trial studies the effects of ONC206, a new drug that stresses out cancer cells to kill them, in children and young adults with difficult-to-treat brain tumors. The drug can be used alone or with radiation therapy. ONC206 is related to ONC201, which has shown promise in treating certain types of brain tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:2 - 21
Key Eligibility Criteria
Disqualifiers:Immune Disorders, Uncontrolled Infection, Others
Must Not Be Taking:Investigational Drugs, Anti-cancer Agents
208 Participants Needed
Immunotherapy Before and After Surgery for Brain Tumor
Philadelphia, Pennsylvania
This trial studies the effects of nivolumab, an immunotherapy drug, in children and young adults with severe brain cancer that has returned or worsened. The drug helps the immune system fight the cancer and may prevent it from growing.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:6 - 25
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Brainstem Tumor, Active Infection, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids
20 Participants Needed
PARP Inhibitor + Temozolomide for Brain Cancer
Philadelphia, Pennsylvania
This trial studies the safety and best dose of BGB-290 and temozolomide in treating young people with a specific type of brain tumor. BGB-290 blocks enzymes needed for tumor growth, while temozolomide kills or stops cancer cells from growing. The goal is to find out if this combination works better for these patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:13 - 25
Key Eligibility Criteria
Disqualifiers:Active Infection, Other Malignancy, Bleeding Disorder, Others
Must Not Be Taking:PARP Inhibitors, Anticoagulants
78 Participants Needed
Bevacizumab for Glioblastoma
Philadelphia, Pennsylvania
The high-grade malignant brain tumor glioblastoma multiforme (GBM) comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for GBM. Initial therapy consists of surgical resection, external beam radiation or both. Currently, all patients experience a recurrence after this first-line therapy, so improvements in both first-line and salvage therapy are critical to enhancing quality-of-life and prolonging survival. Superselective Intraarterial Cerebral Infusion (SIACI) is a technique that can effectively increase the concentration of drug delivered to the brain while sparing the body of systemic side effects. This technique threads a tiny catheter through the patient's femoral artery in the leg, up through the body and neck and into the brain. Once the catheter reaches the brain, chemotherapy is released to the blood vessels that feed the tumor.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, Lactation, Significant Medical Conditions
30 Participants Needed
ASP8374 + Cemiplimab for Recurrent Brain Cancer
Philadelphia, Pennsylvania
This trial is testing the safety and effectiveness of combining two drugs, ASP8374 and cemiplimab, for people with recurrent brain cancer. The study aims to find the best dose and see if the combination helps before surgery. The drugs work by boosting the immune system to fight cancer cells. Cemiplimab has been previously tested in combination with other treatments for severe cancers.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Active Infection, Autoimmune, Others
Must Not Be Taking:Anti-VEGF, Immunosuppressants
14 Participants Needed
RSC-1255 for Advanced Cancers
Philadelphia, Pennsylvania
This trial tests RSC-1255, an oral drug designed to block proteins that help cancer cells grow. It targets adults with advanced solid tumors who have not responded to or cannot tolerate other treatments. The goal is to find a safe dose and see how well the drug works.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Cancer Therapy, Cardiovascular Disease, Gilbert's, Others
134 Participants Needed
Navtemadlin for Brain Cancer
Philadelphia, Pennsylvania
This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Uncontrolled Illness, Active Infection, Cardiac Arrhythmia, Others
Must Be Taking:Corticosteroids
32 Participants Needed
Why Other Patients Applied
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
Optune + Radiation & Chemotherapy for Brain Cancer
Philadelphia, Pennsylvania
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Pregnancy, Psychiatric Conditions, Liver Impairment, Others
Must Be Taking:Temozolomide
982 Participants Needed
Personalized Radiation Therapy for Glioblastoma
Philadelphia, Pennsylvania
This trial is testing if giving customized higher doses of radiation can help patients with aggressive brain cancer live longer without their disease getting worse. The study will also look at side effects and overall survival.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Gliadel Wafers, Other Malignancy, Others
20 Participants Needed
Intensity-Modulated Radiation Therapy for Brain Tumor
Philadelphia, Pennsylvania
This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Diabetes, Smoking, Pregnancy, Others
125 Participants Needed
Selinexor + Radiation for Brain Cancer
Philadelphia, Pennsylvania
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:12 - 21
Key Eligibility Criteria
Disqualifiers:Not Listed
210 Participants Needed
Adavosertib + Radiation + Temozolomide for Glioblastoma
Philadelphia, Pennsylvania
This trial tests the safety and best dose of adavosertib combined with radiation and temozolomide for treating glioblastoma. Adavosertib blocks enzymes needed for tumor growth, while radiation and temozolomide kill cancer cells and stop them from growing. The study aims to find the most effective dose and understand how well this combination works for patients with newly diagnosed or recurrent glioblastoma.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
74 Participants Needed
Tocilizumab + Atezolizumab + Radiation Therapy for Glioblastoma
Philadelphia, Pennsylvania
This trial tests a combination of tocilizumab, atezolizumab, and precise radiation therapy in patients with recurrent glioblastoma. Tocilizumab reduces inflammation, atezolizumab boosts the immune system, and the radiation targets the tumor. The goal is to make the tumor more responsive to treatment and improve patient outcomes.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:IDH Mutation, Bevacizumab, Transplant, Others
Must Not Be Taking:Anti-PD-1, Anti-PD-L1, Anti-CTLA-4, Others
53 Participants Needed
Ribociclib + Everolimus for Brain Tumors
Philadelphia, Pennsylvania
This trial is testing whether the combination of ribociclib and everolimus can help children and young adults with aggressive brain tumors live longer. Everolimus is a medication that has been approved for treating various cancers. These drugs are taken by mouth and work by stopping cancer cells from growing. The study focuses on patients whose tumors have specific genetic changes that make them hard to treat with standard therapies.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 39
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Infection, Others
Must Not Be Taking:Investigational Drugs, Anticancer Agents, Others
100 Participants Needed
Lorlatinib for Brain Tumors
Philadelphia, Pennsylvania
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Early Phase 1
Age:1 - 21
Key Eligibility Criteria
Disqualifiers:Pregnancy, Organ Transplant, Psychiatric Disorder, Others
Must Not Be Taking:Investigational Drugs, Anti-cancer Agents
15 Participants Needed
Ipilimumab + Nivolumab + Radiation for Glioblastoma
Philadelphia, Pennsylvania
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Autoimmune Disease, Others
Must Not Be Taking:Corticosteroids, Warfarin
159 Participants Needed
TTFields for Brain Cancer
Philadelphia, Pennsylvania
This research study is for Glioblastoma (GBM) patients who will be beginning Optune as part of their clinical care, which is a novel treatment that utilizes - tumor treating fields (TTFields), (aka, electrical therapy), which has shown to improve overall survival in large multi-center trials. As a part of this study, participants will either receive Optune with "standard array mapping" (based on regular contrast enhanced MRI) or an "alternative (more precise) array mapping" based on sophisticated state of the art MRI techniques including "whole brain spectroscopy". Whole brain MRI spectroscopy provides additional metabolic information to map out the full extent of tumor spreading within the brain (far beyond from what is seen on regular MRI), by identifying certain metabolites that are present in cancer cells versus healthy tissue. This study is being performed to show whether alternative array mapping improves treatment outcomes, as opposed to the standard array mapping, by maximizing delivery of TTFields dose, thereby achieving more effective tumor cell killing, decreasing the rate of local recurrence, and improving the overall survival as well as quality of life measures.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Implanted Devices, Others
155 Participants Needed
Know someone looking for new options?
Spread the word